EMI (Encore Medical) Inventories, Finished Goods: $0.02 Mil (As of Dec. 2025)


What is Encore Medical Inventories, Finished Goods?

Encore Medical EMI Inventories, Finished Goods is $0.02 Mil as of Dec. 2025.

Encore Medical's quarterly finished goods increased from Jun. 2025 ($0.12 Mil) to Sep. 2025 ($0.18 Mil) but then declined from Sep. 2025 ($0.18 Mil) to Dec. 2025 ($0.02 Mil).

Encore Medical's annual finished goods increased from Dec. 2023 ($0.06 Mil) to Dec. 2024 ($0.15 Mil) but then declined from Dec. 2024 ($0.15 Mil) to Dec. 2025 ($0.02 Mil).

Encore Medical Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Encore Medical's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Encore Medical Inventories, Finished Goods Chart

Encore Medical Annual Data
Trend Dec23 Dec24 Dec25
Inventories, Finished Goods
0.06 0.15 0.02

Encore Medical Quarterly Data
Dec23 Sep24 Dec24 Jun25 Sep25 Dec25
Inventories, Finished Goods Get a 7-Day Free Trial 0.00 0.15 0.12 0.18 0.02

Encore Medical Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of $0.02 Mil mean?
Encore Medical (EMI) has a Inventories, Finished Goods of $0.02 Mil as of Dec. 2025. Finished goods are inventory items that are complete and ready to be sold. View historical data on Encore Medical and its competitors.
Is Encore Medical's Inventories, Finished Goods too high?
Encore Medical's current Inventories, Finished Goods is $0.02 Mil.
How does Encore Medical's Inventories, Finished Goods compare to ?
Encore Medical's Inventories, Finished Goods of $0.02 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Medical Devices & Instruments company?
A good Inventories, Finished Goods depends on the Medical Devices & Instruments industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Encore Medical and its competitors. Encore Medical's current Inventories, Finished Goods is $0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Encore Medical stock overvalued right now?
Encore Medical (EMI) has a current Inventories, Finished Goods of $0.02 Mil. The current Inventories, Finished Goods is $0.02 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Encore Medical (EMI), the current Inventories, Finished Goods is $0.02 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Encore Medical Business Description

Comparable Companies
Address 2975 Lone Oak Drive, Suite 140, Eagan, MN, USA, 55121
Encore Medical Inc develops, manufactures, and markets septal occlusion devices for the repair of certain cardiac defects. Its products have been implanted in approximately 35,000 patients outside the United States. Its closure device is designed to correct a cardiac defect, generally diagnosed in adulthood, known as a patent foramen ovale (PFO). The company also currently market and sell septal occlusion devices for the transcatheter closure of atrial septal defects (ASD).